
|Videos|March 14, 2022
What the re:Vive 2.0 platform may mean for the future of vision diagnostics
Author(s)Sheryl Stevenson
Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.
Advertisement
Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Duravyu misses LUGANO endpoint but cuts treatment burden by 42%
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5


















